SmartPharm Therapeutics develops non-viral gene-encoded therapeutics to provide a protective treatment against COVID-19 through a DNA-based neutralizing antibody delivered via intramuscular injection. Their technology minimizes immunogenicity, allows for re-dosing, and simplifies manufacturing and regulatory processes compared to traditional viral-vectored gene therapies.
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional viral-vectored gene therapies for treating diseases like COVID-19 can trigger strong immune responses, preventing re-dosing and requiring immune suppression. Manufacturing these therapies is complex and expensive, while regulatory pathways can be challenging.
Solution
SmartPharm Therapeutics develops non-viral gene-encoded therapeutics (GET) as a protective treatment against COVID-19, delivered via intramuscular injection of a DNA-based neutralizing antibody. Their platform minimizes immunogenicity, enabling re-dosing without immune suppression. The GET approach also simplifies scalable, economic cGMP manufacturing and reduces regulatory complexity compared to traditional viral-vectored gene therapies. SmartPharm's technology includes both DNA and mRNA approaches, allowing them to select the optimal nucleic acid based on the specific therapeutic target and purpose.
Target Audience
The primary target audience includes individuals at risk of COVID-19 infection and healthcare providers seeking protective treatments.
Features
- DNA-based neutralizing antibody delivered via intramuscular injection
- Minimally immunogenic, eliminating the need for immune suppression
- Re-dosable in patients
- Scalable, economic cGMP manufacturing
- Reduced regulatory complexity
- Platform technology includes both DNA and mRNA approaches
- Protein sequence tuned for use with the specific nucleic acid platform and therapeutic application